Dispirooxindoles Based on 2-Selenoxo-Imidazolidin-4-Ones: Synthesis, Cytotoxicity and ROS Generation Ability
Open Access
- 5 March 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5), 2613
- https://doi.org/10.3390/ijms22052613
Abstract
A regio- and diastereoselective synthesis of two types of dispiro derivatives of 2-selenoxoimidazolidin-4-ones, differing in the position of the nitrogen atom in the central pyrrolidine ring of the spiro-fused system—namely, 2-selenoxodispiro[imidazolidine-4,3′-pyrrolidine-2′,3″-indoline]-2″,5-diones (5a-h) and 2-senenoxodispiro[imidazolidine-4,3′-pyrrolidine-4′,3″-indoline]-2″,5-diones (6a-m)—were developed based on a 1,3-dipolar cycloaddition of azomethine ylides generated from isatin and sarcosine or formaldehyde and sarcosine to 5-arylidene or 5-indolidene-2-selenoxo-tetrahydro-4H-imidazole-4-ones. Selenium-containing dispiro indolinones generally exhibit cytotoxic activity near to the activity of the corresponding oxygen and sulfur-containing derivatives. Compounds 5b, 5c, and 5e demonstrated considerable in vitro cytotoxicity in the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) test (concentration of compounds that caused 50% death of cells (CC50) 7.6–8.7 μM) against the A549 cancer cell line with the VA13/A549 selectivity index 5.2–6.9; some compounds (5 and 6) increased the level of intracellular reactive oxygen species (ROS) in the experiment on A549 and PC3 cells using platinized carbon nanoelectrode. The tests for p53 activation for compounds 5 and 6 on the transcriptional reporter suggest that the investigated compounds can only have an indirect p53-dependent mechanism of action. For the compounds 5b, 6b, and 6l, the ROS generation may be one of the significant mechanisms of their cytotoxic action.Funding Information
- Russian Foundation for Basic Research (19-03-00201, 20-33-90008)
- Russian Science Foundation (19-79-30062)
- Competitiveness Program of NUST “MISIS” (Governmental decree dated March 16, 2013, No. 211)
This publication has 52 references indexed in Scilit:
- The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon CancerPLOS ONE, 2013
- Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerizationProceedings of the National Academy of Sciences of the United States of America, 2012
- Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastasesEuropean Journal of Medicinal Chemistry, 2012
- Tumor Vascular Maturation and Improved Drug Delivery Induced by Methylselenocysteine Leads to Therapeutic Synergy with Anticancer DrugsClinical Cancer Research, 2008
- PBISe, a novel selenium-containing drug for the treatment of malignant melanomaMolecular Cancer Therapeutics, 2008
- Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathwayProceedings of the National Academy of Sciences of the United States of America, 2008
- From Selenium to Selenoproteins: Synthesis, Identity, and Their Role in Human HealthAntioxidants and Redox Signaling, 2007
- Synthesis and Properties of Novel Imidazolone Derivatives Containing a Sulfur AtomPhosphorus, Sulfur, and Silicon and the Related Elements, 2007
- Sulfur and Selenium: The Role of Oxidation State in Protein Structure and FunctionAngewandte Chemie, 2003
- Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissuesJournal of Steroid Biochemistry, 1979